New study tracks Maribavir's Real-World success against Post-Transplant CMV

NCT ID NCT06677892

Ongoing Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study follows 75 adults who have had a stem cell or solid organ transplant and are being treated with maribavir for cytomegalovirus (CMV) infection. Researchers will track how well the drug clears the virus, how long treatment lasts, and any side effects. The goal is to see how maribavir works in everyday medical practice under Belgian reimbursement rules.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: maribavir
What this could lead to: If successful, this study could confirm that maribavir is a safe and effective option for treating CMV after transplant in real-world settings.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. CMV recurrence or drug resistance could still occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYTOMEGALOVIRUS (CMV)

Contacts and locations

Locations

CHU UCL Namur - site Godinne

Yvoir, 5530, Belgium
CHU de Liège - site Sart Tilman

Liège, 4000, Belgium
Cliniques Universitaires Saint-Luc

Brussels, 1200, Belgium
Hôpital Erasme

Anderlecht, 1070, Belgium
Institut Jules Bordet

Anderlecht, 1070, Belgium
UZA

Edegem, 2640, Belgium
UZBrussel

Jette, 1090, Belgium
UZGent

Ghent, 9000, Belgium
UZLeuven

Leuven, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.